Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

Abstract Background The 2020 National Comprehensive Cancer Network guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab‐paclitaxel (G‐nP) for borderline resectable/locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC). Aim The purpose of our study was to compare t...

Full description

Bibliographic Details
Published in:	Cancer Reports
Main Authors:	Myles A. Ingram, Brianna N. Lauren, Yoanna Pumpalova, Jiheum Park, Francesca Lim, Susan E. Bates, Fay Kastrinos, Gulam A. Manji, Chung Yin Kong, Chin Hur
Format:	Article
Language:	English
Published:	Wiley 2022-09-01
Subjects:	chemotherapy clinical cancer research pancreatic cancer
Online Access:	https://doi.org/10.1002/cnr2.1565

Similar Items

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
by: Volker Kunzmann, et al.
Published: (2014-09-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-05-01)

Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
by: Syvart Dennen, et al.
Published: (2025-08-01)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
by: Masashi Sawada, et al.
Published: (2020-05-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
by: Taro Shibuki, et al.
Published: (2024-07-01)

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
by: Mitsuru Kinoshita, et al.
Published: (2022-09-01)

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure
by: Hui Tang, et al.
Published: (2025-09-01)

Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
by: Lenka N.C. Boyd, et al.
Published: (2024-09-01)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
by: Masaru Fukahori, et al.
Published: (2023-11-01)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
by: Annalisa Comandatore, et al.
Published: (2022-01-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
by: Qi Quan, et al.
Published: (2020-12-01)

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
by: Ken Kamata, et al.
Published: (2023-09-01)

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
by: Emerson Y. Chen, et al.
Published: (2023-06-01)

Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review
Published: (2019-08-01)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
by: Taro Shibuki, et al.
Published: (2022-01-01)

Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01)

Efficacy and safety of neoadjuvant nab‐paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single‐arm phase II study (NAC‐GA trial)
by: Ken‐ichi Okada, et al.
Published: (2023-11-01)

Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
by: Agata Adamczuk-Nurzyńska, et al.
Published: (2025-04-01)

Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
by: Yoo Jin Choi, et al.
Published: (2021-05-01)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
by: Tsuyoshi Shirakawa, et al.
Published: (2023-05-01)

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study
by: Carlos Escriva-Aranda, et al.
Published: (2026-06-01)

Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy
by: Ziyi Yang, et al.
Published: (2022-08-01)

Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein
by: Chunyan Li, et al.
Published: (2022-11-01)

Efficacy and Safety of Different Sequences for mFOLFIRINOX (or SOXIRI) and Gemcitabine Plus Albumin-Bound Paclitaxel in Unresectable Pancreatic Cancer
by: Huang S, et al.
Published: (2025-10-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
by: Zhou Zhu, et al.
Published: (2023-10-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
by: I. A. Pokataev, et al.
Published: (2019-12-01)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
by: Heejung Chae, et al.
Published: (2020-05-01)

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer
by: Margaret M. Byrne, et al.
Published: (2024-07-01)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
by: Haorui Li, et al.
Published: (2023-10-01)

GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer
by: Sophie Gourgou, et al.
Published: (2025-08-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
by: Shuling Chen, et al.
Published: (2023-03-01)

Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
by: Tsuyoshi Shirakawa, et al.
Published: (2024-03-01)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
by: Catalano M, et al.
Published: (2020-10-01)

Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
by: Takahiro Murokawa, et al.
Published: (2022-02-01)

Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model
by: Md. Hafiz Uddin, et al.
Published: (2023-12-01)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
by: Konstantin Schlick, et al.
Published: (2023-08-01)

Excellent Biochemical Response to Polychemotherapy with Nab-Paclitaxel/Gemcitabine in an 82-Year-Old Female with Metastatic Breast Cancer
by: Siegfried J. Völkl
Published: (2014-09-01)

Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis
by: S. Banks, et al.
Published: (2024-03-01)

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
by: Ruihua Xu, et al.
Published: (2017-12-01)